Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
SourceMultiple Sclerosis International, 2020, (2020), article 5463451
Article / Letter to editor
Display more detailsDisplay less details
Multiple Sclerosis International
SubjectRadboudumc 18: Healthcare improvement science RIHS: Radboud Institute for Health Sciences
Background: Recently, ocrelizumab (Ocrevus(R)) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered. Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting. Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration). Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p </= .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start. Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.